2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

101. Red Cells and Erythropoiesis, Excluding Iron: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Cell Expansion, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Bone Marrow Failure Syndromes, Genetic Disorders, Hemoglobinopathies, Thalassemia, Immunology, Autoimmune Hemolytic Anemia, Infectious Diseases, Myeloid Malignancies, Metabolic Disorders, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

1103 Toward risk-adapted therapy for pediatric autoimmune hemolytic anemia: A single-center retrospective cohort study

Sofia Maria Carlotta Arnaboldi, MD, Camilla Cellarius2, Melanie Kirby-Allen, MD3, Reena Pabari, MD, MSc, FRCPC4, Clarisse Emily Carcao, N/A5, Sheila Butchart, RN6, Michelle Fantauzzi, RN7, Diandra Rollan, RN8, Jillian Margaret Baker, MD, M.Sc., FRCPC9, Manuel Carcao, MD10
1 The Hospital for Sick Children, Toronto, Ontario, Canada
2 The Hospital for Sick Children, Toronto, Ontario, Canada
3 The Hospital for Sick Children, Toronto, Ontario, Canada
4 The Hospital for Sick Children, Toronto, Ontario, Canada
5 The Hospital for Sick Children, Toronto, Ontario, Canada
6 The Hospital for Sick Children, Toronto, Ontario, Canada
7 The Hospital for Sick Children, Toronto, Ontario, Canada
8 The Hospital for Sick Children, Toronto, Ontario, Canada
9 The Hospital for Sick Children, Toronto, Ontario, Canada, Unity Health Toronto (St. Michael’s Hospital), Toronto, Ontario, Canada
10 The Hospital for Sick Children, Toronto, Ontario, Canada

Introduction. Autoimmune hemolytic anemia (AIHA) is a rare disorder characterized by accelerated antibody-mediated red blood cell destruction, resulting in potentially life-threatening hemolysis. The rarity and clinical heterogeneity of pediatric AIHA have limited the availability of high-quality evidence to guide diagnosis and management. AIHA can be subdivided into warm/cold/mixed antibody AIHA or paroxysmal cold hemoglobinuria (PCH). While warm and mixed forms are usually managed with corticosteroids, PCH is usually self-limited, and cold AIHA is not effectively treated with corticosteroids. No prospective studies have defined the optimal duration of corticosteroid therapy or second-line treatment strategies for pediatric warm/mixed AIHA, despite the well-recognized toxicity of prolonged corticosteroid exposure. Identifying patients at increased risk of treatment failure and relapse at presentation may enable risk-adapted therapeutic strategies to minimize corticosteroid-related morbidity while maintaining disease control. We therefore conducted a retrospective cohort study to identify clinical and immunological factors predictive for response to corticosteroid treatment in children with AIHA.

Methods. We performed a single-center retrospective cohort study including all patients ≤18 years of age treated for AIHA at The Hospital for Sick Children (Toronto, Canada) between 01/2018 and 01/2026. Data was collected through medical record review. The primary objective was to identify baseline clinical and laboratory characteristics associated with failure to achieve complete response (CR) to corticosteroid therapy in patients with warm/mixed AIHA. CR was defined as normalization of hemoglobin, with resolution of hemolysis without requiring second-line therapies. Secondary objectives included evaluation of characteristics of patients with relapsed disease, time to relapse and corticosteroid treatment duration.  Relapse was defined as recurrent hemolytic anemia after achievement of CR.

Results. Eighty-four patients (38 male:46 female) were included (mean age at diagnosis 3.2 years, median 5.4, range 0.25–18.8). Secondary forms of AIHA were identified in 33 patients: post-transplant AIHA (n=15), systemic lupus erythematosus (n=13), primary immunodeficiency (n=2), chronic hepatitis C (n=1), autoimmune lymphoproliferative syndrome (n=1) and leukemia (n=1). The remaining 51 patients were classified as having primary AIHA. Warm AIHA was the most common subtype (n=45, 53.6%), followed by PCH (n=13, 15.5%), cold agglutinin disease (n=12, 14.3%), mixed AIHA (n=11, 13.1%) and DAT-negative AIHA (n=3, 3.6%).

Among the 56 patients with warm/mixed AIHA, 52 were treated with corticosteroids. CR to corticosteroids varied significantly from 75% (12/16) in those with primary warm AIHA to 36% (9/25) in those with secondary warm AIHA (χ²=5.94, p=0.015), to 11.1% (1/9) in those with primary mixed AIHA to 0% (0/2) in those with secondary mixed AIHA (Fisher's exact test, OR 10.5, p=0.016). Overall, 22 patients with warm/mixed AIHA achieved CR with corticosteroids alone, whereas 30 failed to achieve CR. Of these 30 patients, 21 received second-line therapy in addition to corticosteroids (MMF n=3; IVIG n=3; sirolimus n=2; tacrolimus n=1; hydroxychloroquine n=1; combination therapy n=11). The remaining 9 patients did not receive any additional treatment beyond corticosteroids, and 6 subsequently relapsed.

Fifteen of 16 patients with primary warm AIHA received a short corticosteroid course (median 2 months, range 4 days–3 months); only one relapse occurred 9 months after diagnosis. Patients with secondary warm AIHA received substantially longer corticosteroid treatment (median 6 months, range 4 days–5 years), reflecting either persistent hemolysis or treatment of the underlying disease, and 6 relapses were observed (median time to relapse 4.1 months, range 1.0–10.1 months).

Conclusions. Children with primary warm AIHA appear to represent a subgroup characterized by excellent response to corticosteroids and a low risk of relapse, suggesting that a short course of corticosteroid may be sufficient. In contrast, patients with secondary warm AIHA and those with mixed AIHA have a substantially higher risk of corticosteroid treatment failure, supporting early integration of additional immunosuppressive therapy. These findings may inform the design of a prospective interventional trial evaluating risk-adapted treatment strategies in pediatric AIHA.

Sofia Maria Carlotta Arnaboldi, MD: No relevant conflicts of interest to declare.